Skip to main content
Advertisement
Advertisement

RLAY

RLAY logo

Relay Therapeutics, Inc. Common Stock

17.98
USD
Sponsored
+0.10
+0.56%
Oct 12, 15:59 UTC -4
Closed
exchange

After-Market

18.15

+0.17
+0.95%

RLAY Earnings Reports

Positive Surprise Ratio

RLAY beat 14 of 25 last estimates.

56%

Next Report

Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$239.70K
/
-$0.40
Implied change from Q2 26 (Revenue/ EPS)
-31.51%
/
-2.44%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-6.98%

Relay Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 06, 2026, RLAY reported earnings of -0.41 USD per share (EPS) for Q2 26, missing the estimate of -0.39 USD, resulting in a -2.78% surprise. Revenue reached 350.00 thousand, compared to an expected 890.18 thousand, with a -60.68% difference. The market reacted with a +0.10% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 9 analysts forecast an EPS of -0.40 USD, with revenue projected to reach 239.70 thousand USD, implying an decrease of -2.44% EPS, and decrease of -31.51% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
NanoViricides Inc.
Report Date
Sep 28, 2026 For Q4 26
Estimate
-$0.10
Actual
-$0.10
Surprise
+1.96%
FAQ
For Q2 2026, Relay Therapeutics, Inc. Common Stock reported EPS of -$0.41, missing estimates by -2.78%, and revenue of $350.00K, -60.68% below expectations.
The stock price moved up 0.1%, changed from $19.75 before the earnings release to $19.77 the day after.
The next earning report is scheduled for Nov 04, 2026.
Based on 9 analysts, Relay Therapeutics, Inc. Common Stock is expected to report EPS of -$0.40 and revenue of $239.70K for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement